Quinine Global Market Opportunities and Strategies to 2035

This report describes and explains the quinine market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global quinine market reached a value of nearly $2.46 billion in 2025, having grown at a compound annual growth rate (CAGR) of 7.1% since 2020. The market is expected to grow from $2.46 billion in 2025 to $3.38 billion in 2030 at a rate of 6.6%. The market is then expected to grow at a CAGR of 5.4% from 2030 and reach $4.41 billion in 2035.

Growth in the historic period resulted from high global prevalence of malaria, public-private partnerships in malaria eradication programs, rising public health programs and government procurement of antimalarial drugs and rising demand for tonic water and bitter beverages. Factors that negatively affected growth in the historic period were shift toward artemisinin-based combination therapies (acts) reducing reliance and side effects and toxicity concerns.

Going forward, increasing off-label use for nocturnal leg cramps treatment, efforts towards the support for cinchona cultivation and processing, increasing rural healthcare penetration in malaria-endemic regions and support from global health organizations (WHO malaria programs) will drive the growth. Factors that could hinder the growth of the quinine market in the future include stringent regulatory restrictions, reduced physician preference due to side-effect profile and availability of synthetic bittering alternatives in beverages.

Market trends for the quinine market include expansion of quinine applications in premium beverage segment through product innovation and focus on premium mixer offerings with innovative flavors.

The quinine market is segmented by product into quinine sulphate, quinine hydrochloride, quinine gluconate and quinine bisulphate. The quinine sulphate was the largest segment of the quinine market segmented by product, accounting for 54.4% or $1.34 billion of the total in 2025. Going forward, the quinine hydrochloride segment is expected to be the fastest-growing segment in the quinine market segmented by product, at a CAGR of 9.2% during 2025-2030.

The quinine market is segmented by administration into oral administration, intramuscular administration, intravenous administration and other administrations. The oral administration market was the largest segment of the quinine market segmented by administration, accounting for 69% or $1.7 billion of the total in 2025. Going forward, the oral administration segment is expected to be the fastest-growing segment in the quinine market segmented by administration, at a CAGR of 7% during 2025-2030.

The quinine market is segmented by application into malaria treatment, nocturnal leg cramps and other applications. The malaria treatment market was the largest segment of the quinine market segmented by application, accounting for 62.7% or $1.54 billion of the total in 2025. Going forward, the other applications segment is expected to be the fastest-growing segment in the quinine market segmented by application, at a CAGR of 10% during 2025-2030.

The quinine market is segmented by end user into hospitals, clinics and other end users. The hospitals market was the largest segment of the quinine market segmented by end user, accounting for 49.5% or $1.22 billion of the total in 2025. Going forward, the other end users segment is expected to be the fastest-growing segment in the quinine market segmented by end user, at a CAGR of 8.5% during 2025-2030.

Africa was the largest region in the quinine market, accounting for 47.96% or $1.18 billion of the total in 2025. It was followed by Asia Pacific, South America and then the other regions. Going forward, the fastest-growing regions in the quinine market will be Asia Pacific and Western Europe where growth will be at CAGRs of 8.18% and 6.54% respectively. These will be followed by Eastern Europe and North America where the markets are expected to grow at CAGRs of 6.46% and 6.36% respectively.

The global quinine market is highly fragmented, with large number of small players operating in the market. The top 10 competitors in the market made up 4.772% of the total market in 2024. Alchem International Private Ltd was the largest competitor with a 0.946% share of the market, followed by PT Sinkona Indonesia Lestari with 0.873%, SimSon Pharma Limited with 0.631%, Sun Pharmaceutical Industries Ltd. with 0.557%, Lupin Limited with 0.438%, Dayang chem (Hangzhou) Co., Ltd. with 0.307%, Cipla Limited with 0.281%, Vital Laboratories Private Limited with 0.251%, Pharmakina SA with 0.246% and Merck KGaA with 0.242%.

The top opportunities in the quinine market segmented by product will arise in the quinine sulphate segment, which will gain $466.5 million of global annual sales by 2030. The top opportunities in the quinine market segmented by administration will arise in the oral administration segment, which will gain $688.6 million of global annual sales by 2030. The top opportunities in the quinine market segmented by application will arise in the malaria treatment segment, which will gain $429.2 million of global annual sales by 2030. The top opportunities in the quinine market segmented by end user will arise in the hospitals segment, which will gain $485.9 million of global annual sales by 2030. The quinine market size will gain the most in the India at $138.2 million.

Player-adopted strategies in the quinine market include focus on strengthening its business operations through strategic partnerships.

Market-trend-based strategies for the quinine market include focus on expanding its application in the premium food and beverage sector and focus on premium beverage portfolios through innovative tonic water variants.

To take advantage of the opportunities, the analyst recommends the focus on premium beverage expansion and lifestyle positioning, focus on premium mixer innovation and multi-channel distribution, focus on quinine hydrochloride for hospital and injectable applications, focus on oral administration for mass treatment and outpatient demand, expand in emerging markets, continue to focus on developed markets, focus on tiered pricing and value-based product positioning, focus on healthcare awareness and clinical education campaigns, focus on premium beverage branding and consumer engagement, focus on premium beverage and niche non-malarial applications, focus on government, research and humanitarian end-user expansion.

This product will be delivered within 3-5 business days.